Proteome Sciences plc (LON:PRM) Chief Executive Officer Jeremy Haigh talks to DirectorsTalk about it’s positive year end results. With a 46% jump in revenues for last year, Jeremy explains what the key drivers were behind this, more about it’s twin pronged growth strategy – in proteomics and bioinformatics, how the company will benefit from a trend in ‘personalised medicine’ and what we should expect for the rest of the year.
Proteome Sciences Plc is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®, TMTcalibrator™) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in London, UK and in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies, and to academia. The company has patented a series of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer’s disease, and these are also available for license.
